Evaluating effect of teriflunomide on cortical atrophy in a subgroup analysis of patients defined by baseline MRI activity in the Phase 3 TOPIC study

被引：0
|
作者：
Zivadinov, R. [1 ]
Dwyer, M. G. [1 ]
Carl, E. [1 ]
Thangavelu, K. [2 ]
Cavalier, S. [2 ]
Bergsland, N. [1 ]
机构：
[1] Univ Buffalo, Buffalo, NY USA
[2] Sanofi Genzyme, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PR2092
引用
收藏
页码：580 / 580
页数：1
相关论文
共 50 条
  • [41] CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF THE PHASE 3 ENDEAVOR STUDY BY AGE SUBGROUP
    Palumbo, A.
    Dimopoulos, M. A.
    Moreau, P.
    Chng, W. J.
    Goldschmidt, H.
    Hajek, R.
    Facon, T.
    Ludwig, H.
    Pour, L.
    Niesvizky, R.
    Oriol, A.
    Rosinol, L.
    Suvorov, A.
    Gaidano, G.
    Pika, T.
    Weisel, K.
    Gillenwater, H. H.
    Goranova-Marinova, V.
    Mohamed, N.
    Feng, S.
    Joshua, D.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
  • [42] Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study
    Hide, Michihiro
    Igarashi, Atsuyuki
    Yagami, Akiko
    Chinuki, Yuko
    Inomata, Naoko
    Fukunaga, Atsushi
    Kaiser, Guenther
    Wang, Junyi
    Matsushima, Soichiro
    Greenberg, Steven
    Khalil, Sam
    ALLERGOLOGY INTERNATIONAL, 2018, 67 (02) : 243 - 252
  • [43] Consistent Lanadelumab Treatment Effect In Patients With Hereditary Angioedema (HAE) Regardless Of Baseline Attack Frequency In The Phase 3 HELP Study
    Riedl, Marc A.
    Tachdjian, Raffi
    Schranz, Jennifer
    Nurse, Christina
    Bernstein, Jonathan A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB47 - AB47
  • [44] Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN)
    Yoo, Albert J.
    Berkhemer, Olvert A.
    Fransen, Puck S. S.
    van den Berg, Lucie A.
    Beumer, Debbie
    Lingsma, Hester F.
    Schonewille, Wouter J.
    Sprengers, Marieke E. S.
    van den Berg, Rene
    van Walderveen, Marianne A. A.
    Beenen, Ludo F. M.
    Wermer, Marieke J. H.
    Nijeholt, Geert J. Lycklama A.
    Boiten, Jelis
    Jenniskens, Sjoerd F. M.
    Bot, Joseph C. J.
    Boers, Anna M. M.
    Marquering, Henk A.
    Roos, Yvo B. W. E. M.
    van Oostenbrugge, Robert J.
    Dippel, Diederik W. J.
    van der Lugt, Aad
    van Zwam, Wim H.
    Majoie, Charles B. L. M.
    LANCET NEUROLOGY, 2016, 15 (07): : 685 - 694
  • [45] Subgroup analysis of leiomyosarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
    Blay, J. Y.
    Schoffski, P.
    Bauer, S.
    Krarup-Hansen, A.
    Benson, C.
    D'Adamo, D.
    Guo, M.
    Maki, R.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S155 - S155
  • [46] Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.
    Selvaggi, G.
    Wu, Y.
    Wang, Z.
    Wu, G.
    Poddubskaya, E.
    Reck, M.
    Mok, T.
    Chiappori, A.
    Lee, D. H.
    Breder, V.
    Orlov, S.
    Cicin, I.
    Cheng, Y.
    Liu, Y.
    Fan, Y.
    Zhou, J.
    Liang, C.
    Mao, L.
    Horn, L.
    Wakelee, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S232 - S233
  • [47] Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
    Hu, Bei
    Reagan, Patrick Michael
    Sehn, Laurie Helen
    Sharman, Jeff Porter
    Hertzberg, Mark
    Zhang, Huilai
    Kim, Austin Injae
    Herbaux, Charles
    Molina, Lysiane
    Maruyama, Dai
    Smolewski, Piotr
    Stenner, Frank
    Craine, Veronica
    Kothari, Rucha
    Hirata, Jamie H.
    Sahin, Deniz
    Sugidono, Matthew Dean Sei
    Lee, Calvin
    Tilly, Herve
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN HYPERKALEMIC PATIENTS WITH CKD ON RAAS INHIBITORS: SUBGROUP ANALYSIS OF PHASE 3 HARMONIZE STUDY
    Qunibi, Wajeh
    Kosiborod, Mikhail
    Rasmussen, Henrik S.
    Lavin, Philip T.
    Yang, Alex
    Lerma, Edgar
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (04) : A70 - A70
  • [49] Subgroup analysis of DIA-AID 1, an immune intervention phase 3 study in newly diagnosed type 1 diabetes patients
    Pozzilli, P.
    Raz, I.
    Linn, T.
    Bonnici, F.
    Elias, D.
    Avron, A.
    Tamir, M.
    Eren, R.
    Dagan, S.
    DIABETOLOGIA, 2013, 56 : S230 - S230
  • [50] Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
    Iwata, Hiroji
    Inoue, Kenichi
    Kaneko, Koji
    Ito, Yoshinori
    Tsugawa, Koichiro
    Hasegawa, Ayumi
    Nakagawa, Shintaro
    Kuratomi, Hiroyasu
    Tamura, Kenji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (12) : 1083 - 1091
12345